A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in a Real-World Setting

NCT: NCT07247084 · Status: RECRUITING · Phase: Phase 4 · Sponsor: Eli Lilly and Company · Started: 2025-11-24 · Est. Completion: 2032-07

Official Summary

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Study Design

Interventions

Primary Outcomes

Secondary Outcomes

Trial Locations

More Obesity Trials

View all Obesity clinical trials

AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.